Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Phillip A. Dennis"'
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Publikováno v:
Anticancer Research. 41:91-99
Background/aim Small-cell lung cancer (SCLC) is aggressive and confers poor prognosis. Although SCLC shows more response to chemotherapy than other types of lung cancer, it is difficult to cure because of its frequent recurrence. New drugs and molecu
Autor:
B. Weiner, J-C. Soria, Phillip A. Dennis, Matthew R. Henn, Christopher B. Ford, Jennifer R. Wortman, Vancheswaran Gopalakrishnan, Scott A. Hammond, Bret R. Sellman, D.J. Freeman
Publikováno v:
Immuno-Oncology and Technology, Vol 6, Iss, Pp 9-17 (2020)
Immunotherapies have drastically improved clinical outcomes in a wide range of malignancies. Nevertheless, patient responses remain highly variable, and reliable biomarkers that predict responses accurately are not yet fully understood. Compelling ev
Autor:
Catherine Wadsworth, Phillip A. Dennis, Alan Sharpe, Marietta Scott, Marianne Ratcliffe, Anne Marie Boothman, Jill Walker, Marina Chiara Garassino, Jessica Whiteley, Naiyer A. Rizvi
Publikováno v:
Journal of Thoracic Oncology. 14:1390-1399
Introduction We evaluated the impact of patient characteristics, sample types, and prior non-immunotherapy treatment on tumor cell (TC) programmed cell death ligand 1 (PD-L1) expression using samples from patients with advanced NSCLC. Methods Patient
Autor:
Brandon W. Higgs, Philip Brohawn, Koustubh Ranade, Michael Kuziora, Phillip A. Dennis, Ashok K. Gupta, Rajiv Raja
Publikováno v:
Clinical Cancer Research. 24:6212-6222
Purpose: Immunotherapy has transformed the treatment of many solid tumors, with some patients deriving long-term benefit, but how to identify such patients remains unclear. Somatic mutations detected in circulating tumor DNA (ctDNA) from plasma can b
Autor:
Jamie E. Chaft, Myung-Ju Ahn, Charles Swanton, Fabrice Barlesi, L. Poole, D. Harpole, David R. Spigel, Solange Peters, R. May, Glenwood D. Goss, Phillip A. Dennis, Masahiro Tsuboi, C. Abbosh
Publikováno v:
Journal of Thoracic Oncology. 16:S258-S259
Publikováno v:
European urology. 78(4)
Autor:
Michiel S. van der Heijden, Qu Zhang, Todd Hembrough, Song Wu, Shaad Essa Abdullah, Han Si, Matthew D. Hellmann, J. Carl Barrett, Wenjing Xu, Chen Gao, Phillip A. Dennis, Brandon Higgs, Neil H. Segal, Jamie E. Chaft, Jia Luo
Publikováno v:
Cancer Discov
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-stage tumor t
Autor:
Michael Cabanero, Xuyang Song, Rosalyn A. Juergens, Penelope A. Bradbury, Phillip A. Dennis, John Hilton, P. Brown-Walker, Desiree Hao, John R. Goffin, Sebastien J. Hotte, Anna Tomiak, Gwyn Bebb, Scott A. Laurie, Andrew Robinson, Martin Smoragiewicz, Christian K. Kollmannsberger, I. Gauthier, Moustapha Tehfe, Xiaoqun Sun, Peter M. Ellis, Dongsheng Tu, Paul Wheatley-Price, Mihaela Mates, Janessa Laskin, Glenwood D. Goss, Lesley Seymour, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du
Autor:
John V. Heymach, D. Harpole, M. Powell, Phillip A. Dennis, Martin Reck, Janis M. Taube, M. Aperghis, Leonardo Trani, Tetsuya Mitsudomi
Publikováno v:
Journal of Thoracic Oncology. 14:S625-S626